Hikma Highlights Long-Term Importance Of Biosimilars

CEO Siggi Olafsson Discusses The Evolution Of Hikma’s Injectables Business

 
• By Dave Wallace

Playing in biosimilars is essential for firms that want to lead in the sterile injectables space, Hikma CEO Siggi Olafsson commented as he discussed how the firm’s injectables business was expected to evolve over the coming years.

Timeline years 2025 blue pin
Hikma sees biosimilars becoming a significant part of its business from 2025 • Source: Olivier Le Moal / Alamy Stock Photo

More from Biosimilars

More from Products